An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...
This review included five randomized controlled trials with 882 participants older than 6 years. 1 All of the studies were published between 1986 and 2019. The studies were not primarily designed to ...
β2 adrenergic receptor (β2AR) agonism improves muscle glucose uptake and whole-body glucose homeostasis in rodents, an effect which is dependent on GPCR kinase 2 (GRK2). However, β2AR agonism has not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results